GlassScriptPhysician profile
William G Paxton
NPI 1710942057
$72,811.31
in general payments reported to CMS, 2019-2025
19 companies · $54.55 in 2025
The $54.55 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $19K · 2021: $25K · 2022: $14K · 2023: $57.95 · 2025: $54.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $112.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $47,351.45 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $14,711.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $8,235.11 | 2019-2021 | |
| Pfizer INC. | $820.82 | 2019 | |
| Vifor Pharma, INC. | $308.90 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $295.09 | 2019-2020 | |
| Akebia Therapeutics INC | $273.69 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $232.93 | 2019-2021 | |
| Amgen INC. | $134.57 | 2019-2021 | |
| Baxter Healthcare | $95.53 | 2019-2023 | Renal - Pd |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.62 | 2021 | |
| Daiichi Sankyo INC. | $67.07 | 2019-2021 | |
| Vantive US Healthcare LLC | $54.55 | 2025 | Renal - Pd |
| Genentech USA, INC. | $48.44 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $47.04 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $23.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.98 | 2021 | |
| Travere Therapeutics, INC. | $13.95 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Paxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.